Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL5917342 | 1.00 | MGAM (0.46) | MGAMGAASIMGAM2HTR2A | |
| Oxalic Acid SCHEMBL5917387 | 1.00 | MGAM (0.46) | MGAMGAASIMGAM2HTR2A | |
| Oxalic Acid SCHEMBL5662735 | 1.00 | MGAM (0.46) | MGAMGAASIMGAM2HTR2A | |
| Oxalic Acid SCHEMBL5917336 | 1.00 | MGAM (0.46) | MGAMGAASIMGAM2HTR2A | |
| SCHEMBL20450109 | 0.78 | HTR2A (0.56) | HTR2ATAAR1 | |
| SCHEMBL5917373 | 0.75 | CYP2D6 (0.57) | HTR2ATAAR1 | |
| SCHEMBL5663639 | 0.75 | CYP2D6 (0.57) | HTR2ATAAR1 | |
| SCHEMBL5917347 | 0.75 | CYP2D6 (0.57) | HTR2ATAAR1 | |
| SCHEMBL5917351 | 0.75 | CYP2D6 (0.57) | HTR2ATAAR1 | |
| Oxalic Acid SCHEMBL5917366 | 0.75 | HTR2A (0.41) | HTR2ATAAR1LCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106106-A1 | Beta-hydroxyphenylalkylamines and their use for treating glaucoma | VIRGINIA COMMONWEALTH UNIVERSITY | 2006-05-18 | — | — | US | claimed |
| US-20060106106-A1 | Beta-hydroxyphenylalkylamines and their use for treating glaucoma | VIRGINIA COMMONWEALTH UNIVERSITY | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106106-A1 | Beta-hydroxyphenylalkylamines and their use for treating glaucoma | PDE3A, QDPR, PDE2A | MGAM 1383/4885GAA 423/4885SI 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.